![Jignesh Chaudhary, Director Jignesh Chaudhary, Director](https://www.siliconindia.com/images/simag_images/uploaded_images/company_logos/h5q5s.jignesh.jpg)
Jignesh Chaudhary
Director
Heilen Biopharm sets itself apart from other companies by leveraging its team of biotechnologists, pharmacists, and chemical engineers, who possess extensive experience in fractional distillation processes for essential oils. Unlike many cosmetic brands that primarily focus on fragrance, the company places greater emphasis on the medical and professional applications of essential oils. Heilen Biopharm aims to harness the natural therapeutic properties of essential oils to address various disorders, including mental health issues such as depression, anxiety, and insomnia. Furthermore, Heilen Biopharm uses these oils for internal detoxification and purification, making them valuable additions to the practices of Ayurvedic centers, nutraceuticals, and dietitians.
Heilen Biopharm ensures the delivery of superior products through its rigorous quality control measures. A dedicated team of
approval officers and chemists, approved by the Food and Drugs Control Administration (FDCA), Gujarat, oversees the quality control process. By utilizing advanced technologies such as gas chromatography and high performance liquid chromatography(HPLC), Heilen Biopharm analyzes the contents of essential oils and verifies the presence of marker components crucial for addressing specific disorders. Clients can request a certificate of analysis containing gas and HPLC chromatograms or easily access the benchmark analysis from NABL accredited laboratories approved by the Indian government.
Since its establishment in 2015 as an active pharmaceutical ingredient (API)and essential oil trading company, Heilen Biopharm has experienced remarkable growth. Despite the initial challenges of low awareness about essential oils, the company achieved a turnover of INR 60 lakhs in its first year with a modest investment of INR 2.5 lakhs. Even during the disruptions caused by the COVID-19 pandemic, Heilen Biopharm focused on developing new products that proved highly beneficial for patients, particularly those with respiratory issues. "As a result, our turnover reached INR 3.5 crores in 2022, and we believe it will exceed INR 10 crores in 2023", states Jignesh Chaudhary, director at Heilen Biopharm.
With a dedicated team of 20 employees, Heilen Biopharm anticipates substantial growth, expanding its workforce to over 100 individuals in the coming year. Initially, Heilen Biopharm operated solely on e-commerce platforms like Amazon and Flipkart with its own web store on Flipkart while today, the company has expanded offline, offering brand franchises across states and major cities.
To further enhance its manufacturing capabilities and meet the increasing demand, Heilen Biopharm is establishing two dedicated manufacturing units. One unit will be a USFDA-compliant plant exclusively producing health care associated essential oils, such as Brahmi and peppermint. The second unit will focus on cosmeceutical and pharmaceutical formulations. By in vesting in these manufacturing units and employing advanced instrumentation in compliance with USFDA regulations, Heilen Biopharm aims to bolster its production capacity. The company's positive trajectory and strategic direction demonstrate its commitment to innovation and catering to the evolving needs of its customers. "With our commitment to quality assurance and strategic expansion plans, we shall continue revolutionizing the essential oil market with our medicinal focus", concludes Chaudhary.
Heilen Biopharm aims to harness the natural therapeutic properties of essential oils to address various disorders, including mental health issues such as depression, anxiety, & insomnia
Since its establishment in 2015 as an active pharmaceutical ingredient (API)and essential oil trading company, Heilen Biopharm has experienced remarkable growth. Despite the initial challenges of low awareness about essential oils, the company achieved a turnover of INR 60 lakhs in its first year with a modest investment of INR 2.5 lakhs. Even during the disruptions caused by the COVID-19 pandemic, Heilen Biopharm focused on developing new products that proved highly beneficial for patients, particularly those with respiratory issues. "As a result, our turnover reached INR 3.5 crores in 2022, and we believe it will exceed INR 10 crores in 2023", states Jignesh Chaudhary, director at Heilen Biopharm.
With a dedicated team of 20 employees, Heilen Biopharm anticipates substantial growth, expanding its workforce to over 100 individuals in the coming year. Initially, Heilen Biopharm operated solely on e-commerce platforms like Amazon and Flipkart with its own web store on Flipkart while today, the company has expanded offline, offering brand franchises across states and major cities.
To further enhance its manufacturing capabilities and meet the increasing demand, Heilen Biopharm is establishing two dedicated manufacturing units. One unit will be a USFDA-compliant plant exclusively producing health care associated essential oils, such as Brahmi and peppermint. The second unit will focus on cosmeceutical and pharmaceutical formulations. By in vesting in these manufacturing units and employing advanced instrumentation in compliance with USFDA regulations, Heilen Biopharm aims to bolster its production capacity. The company's positive trajectory and strategic direction demonstrate its commitment to innovation and catering to the evolving needs of its customers. "With our commitment to quality assurance and strategic expansion plans, we shall continue revolutionizing the essential oil market with our medicinal focus", concludes Chaudhary.